Copyright © Inderes 2011 - present. All rights reserved.

NextCell Pharma

1.28 SEK

+44.31 %

Less than 1K followers

NXTCL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+44.31 %
+75.10 %
+88.79 %
+44.31 %
+24.03 %
-46.67 %
-77.46 %
-90.12 %
-42.12 %

NextCell Pharma operates in the healthcare sector. The company develops stem cell products that are mainly used in the treatment of autoimmune diabetes and kidney transplantation. A large part of the work consists of stem cell research where the company develops drug candidates that will facilitate and increase acceptance in organ transplantation. In addition, the company owns a stem cell bank. The company was founded in 2014 and has its headquarters in Huddinge.

Read more
Market cap
142.58M SEK
Turnover
6.17M SEK
Revenue
10.94M
EBIT %
-328.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/5
2026

Interim report Q1'26

27/8
2026

Interim report Q2'26

26/11
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.